urologytimes2d
Data reinforce isodose MHFRT as standard of care radiotherapy regimen
“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, ...
urologytimes12h
Neeraj Agarwal, MD, FASCO
Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer ...
urologytimes3d
Chad Ellimoottil, MD, highlights recent telehealth extension
“For all intents and purposes, how you've been practicing telehealth currently is exactly how you'll be able to practice it until September 30," says Chad Ellimoottil, MD, MS. Last week Congress ...
urologytimes3d
FDA reports Urgent Device Field Correction notice for CVAC Aspiration System
Calyxo has identified a new risk of injury when the CVAC System is used in patients with high viscosity fluid in their kidneys at the start of the procedure. Calyxo sent an Urgent Device Field ...
urologytimes2d
Perry Xu, MD
Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer ...
urologytimes4d
Nadofaragene firadenovec maintains safety, efficacy in real-world population
"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH. Nadofaragene firadenovec-vncg (Adstiladrin) was ...
urologytimes4d
Treatment Selection for mCRPC
Panelists discuss how patients with bone-predominant mCRPC, good performance status, adequate bone marrow function, and limited visceral disease are ideal candidates for RAD-ENZ combination therapy, ...
urologytimes4d
Clinical Perspectives on Early Use of RAD-ENZ
Panelists discuss how early implementation of RAD-ENZ combination therapy requires careful consideration of patient characteristics, disease burden, and long-term treatment planning while potentially ...
urologytimes4d
Other Investigational Drug Delivery Systems in NMIBC
Experts briefly discuss investigational mitomycin delivery systems UGN-102 and UGN-103, which are being evaluated in intermediate-risk non–muscle-invasive bladder cancer (NMIBC), and share their ...
urologytimes5d
John P. Mulhall, MD, shares his reaction to the FDA’s testosterone labeling changes
“In 5200 men, very clearly, definitively, irrefutably, it has been shown that testosterone therapy is not associated with MACE over the course of the 12 to 24 months after commencement of testosterone ...
urologytimes4d
Kate H. Kraft, MD, discusses pre-op tamsulosin use in pediatric patients undergoing URS
Kate H. Kraft, MD, MHPE, FACS, FAAP,Benjamin P. Saylor "When we compared the 2 groups, those that received tamsulosin and those that did not, we did find a significant difference with regard to ...
urologytimes4d
How urologists can discuss testosterone labeling changes with patients
"I hope that these new guidelines and the removal of the black box warning on testosterone therapy will help more physicians feel comfortable providing testosterone therapy to men," says Helen L.